These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 33086438)

  • 41. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
    Hibi T; Imai Y; Senoo A; Ohta K; Ukyo Y
    J Gastroenterol; 2017 Oct; 52(10):1101-1111. PubMed ID: 28324167
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.
    Li K; Friedman JR; Chan D; Pollack P; Yang F; Jacobstein D; Brodmerkel C; Gasink C; Feagan BG; Sandborn WJ; Rutgeerts P; De Hertogh G
    Gastroenterology; 2019 Oct; 157(4):1019-1031.e7. PubMed ID: 31279870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis.
    Xu Y; Hu C; Chen Y; Miao X; Adedokun OJ; Xu Z; Sharma A; Zhou H
    J Clin Pharmacol; 2020 Jul; 60(7):889-902. PubMed ID: 32026499
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease.
    Sands BE; Han C; Gasink C; Jacobstein D; Szapary P; Gao LL; Lang Y; Targan S; Sandborn WJ; Feagan BG
    J Crohns Colitis; 2018 Jul; 12(8):883-895. PubMed ID: 29726939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3387-3396.e1. PubMed ID: 37391059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
    Colombel JF; Sandborn WJ; Ghosh S; Wolf DC; Panaccione R; Feagan B; Reinisch W; Robinson AM; Lazar A; Kron M; Huang B; Skup M; Thakkar RB
    Am J Gastroenterol; 2014 Nov; 109(11):1771-80. PubMed ID: 25155227
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort.
    Iborra M; Ferreiro-Iglesias R; Maria Dolores MA; Mesonero Gismero F; Mínguez A; Porto-Silva S; García-Ramírez L; García de la Filia I; Aguas M; Nieto-García L; Suárez Ferrer C; Bastida G; Barreiro-De-Acosta M; Nos P
    Scand J Gastroenterol; 2024 Mar; 59(3):260-268. PubMed ID: 37933161
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
    Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
    Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative Speed of Early Symptomatic Remission With Advanced Therapies for Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
    Ahuja D; Murad MH; Ma C; Jairath V; Singh S
    Am J Gastroenterol; 2023 Sep; 118(9):1618-1625. PubMed ID: 36976548
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
    Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
    Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Etrolizumab for induction of remission in ulcerative colitis.
    Rosenfeld G; Parker CE; MacDonald JK; Bressler B
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.
    Meyer A; Fumery M; Peyrin-Biroulet L; Filippi J; Altwegg R; Bouhnik Y; Serrero M; Laharie D; Roblin X; Nachury M; Abitbol V; Cadiot G; Nancey S; Allez M; Gilletta C; Vuitton L; Savoye G; Nahon S; Bourrier A; Buisson A; Bouguen G; Bourreille A; Viennot S; Carbonnel F; Amiot A
    Scand J Gastroenterol; 2022 Dec; 57(12):1454-1462. PubMed ID: 35819361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
    Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
    J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
    Panés J; Colombel JF; D'Haens GR; Schreiber S; Panaccione R; Peyrin-Biroulet L; Loftus EV; Danese S; Tanida S; Okuyama Y; Louis E; Armuzzi A; Ferrante M; Vogelsang H; Hibi T; Watanabe M; Lefebvre J; Finney-Hayward T; Sanchez Gonzalez Y; Doan TT; Mostafa NM; Ikeda K; Xie W; Huang B; Petersson J; Kalabic J; Robinson AM; Sandborn WJ
    Gastroenterology; 2022 Jun; 162(7):1891-1910. PubMed ID: 35227777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis.
    Bai Y; Sun Y; He Q; Bai X; Yang H
    Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):359-370. PubMed ID: 38407891
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
    Peyrin-Biroulet L; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravatà I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Danese S
    Aliment Pharmacol Ther; 2024 Jan; 59(2):175-185. PubMed ID: 38036946
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
    Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
    Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.